On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted approval for Keytruda Qlex, a new coformulation containing pembrolizumab and berahyaluronidase alfa-pmph. This approval marks a significant development for the drug pembrolizumab, expanding its available formulations and offering a new therapeutic option.
Background
Pembrolizumab, also known by its brand name Keytruda, is a well-established drug. The approval of Keytruda Qlex introduces a novel coformulation that combines pembrolizumab with berahyaluronidase alfa-pmph. This product was developed by MERCK SHARP DOHME, the sponsor.
What this means
The approval of Keytruda Qlex on September 19, 2025, signifies an important advancement in the delivery of pembrolizumab. By coformulating pembrolizumab with berahyaluronidase alfa-pmph, this new product likely aims to provide an alternative method of administration or enhance the patient experience. While the specific details regarding the new formulation's advantages are not provided in the approval notice, such developments often lead to increased convenience for patients and healthcare providers, potentially by reducing administration time or offering a less invasive route compared to traditional intravenous infusions. Clinicians will now have an expanded range of options when prescribing pembrolizumab, allowing for greater flexibility in tailoring treatment plans to individual patient needs and preferences. This approval underscores ongoing efforts to innovate in drug delivery and patient care.
Source
The U.S. Food and Drug Administration (FDA) announced the approval of Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) on September 19, 2025. This information is publicly available on the accessdata.fda.gov website, specifically within the Center for Drug Evaluation and Research (CDER) database, under BLA 761467.